Healthcare experts should be on the lookout for trends related to digital health, prescription drug costs and healthcare coverage in 2025, according to LRVHealth. The post 5 Healthcare Predictions for 2025 from One VC Firm appeared first on MedCity News.
As the Trump administration overhauls government health agencies, partisan trust in these agencies on vaccines has shifted and few express confidence in their ability to carry out key tasks. Most adults are confident in the safety of routine vaccines, but the COVID-19 vaccines remain polarizing with many uncertain about false claims regarding mRNA technology.
PTC Therapeutics said it cannot resolve differences it has with the FDA in interpreting clinical trial data for Translarna, a drug it developed for Duchenne muscular dystrophy. The rare disease drug developer’s decision to withdraw Translarna’s FDA submission comes nearly a year after a negative European regulatory decision for the drug. The post PTC Therapeutics…
Californians in November will weigh in on a ballot initiative to increase scrutiny over the use of health-care dollars — particularly money from a federal drug discount program — meant to support patient care largely for low-income or indigent people. The revenue is sometimes used to address housing instability and homelessness among vulnerable patient populations. Voters…
GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concerns from U.S. and European regulators. The post Alfasigma Pays $300M for Rights to GSK Rare Liver…
Here are three key trends that pharma leaders and clinical operations teams should monitor this year, along with a checklist of strategic priorities to stay ahead. The post Navigating 2025: Three Key Trends Shaping the Future of Pharma appeared first on MedCity News.
Behavioral health doesn’t need tech that replaces people. It needs technology that respects them, amplifying what clinicians do best and helping more people get the care they deserve. The post The Behavioral Health AI Boom Is Real. So Are the Risks appeared first on MedCity News.
Last month, the American Heart Association (AHA) and American College of Cardiology (ACA) put out a statement on how new cardiovascular medical technologies should be evaluated from a cost and value standpoint (Kazi et al. 2025). This is an update from their 2014 cost/value methodology (Anderson et al. 2014). What does the AHA/ACC statement say?…
This analysis of initial rate filings from all 50 states and DC shows ACA Marketplace insurers are proposing a median premium increase of 18% for 2026, more than double last year’s 7% median proposed increase. The analysis includes proposed rate changes by state and insurer.
Some say 2026 will be when people start to realize how difficult it will be to deliver on the promises of AI in healthcare